Actavis sues FDA over generic Celebrex

April 28 Mon Apr 28, 2014 5:51pm EDT

April 28 (Reuters) - Actavis Plc on Monday said it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.

The move follows a similar lawsuit announced Friday by Mylan Inc over generic drug marketing exclusivity for Celebrex. (Reporting by Susan Kelly in Chicago; Editing by Bernard Orr)

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.